Nabriva Therapeutics plc - Ordinary Shares (NBRV): Price and Financial Metrics

Nabriva Therapeutics plc - Ordinary Shares (NBRV): $1.42

0.00 (0.00%)

POWR Rating

Component Grades








Add NBRV to Watchlist
Sign Up

NBRV Price/Volume Stats

Current price $1.42 52-week high $8.45
Prev. close $1.42 52-week low $1.22
Day low $1.35 Volume 717,200
Day high $1.90 Avg. volume 29,344
50-day MA $1.55 Dividend yield N/A
200-day MA $1.78 Market Cap 45.46M

NBRV Stock Price Chart Interactive Chart >

Nabriva Therapeutics plc - Ordinary Shares (NBRV) Company Bio

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company was founded in 2006 and is based in Wien, Austria.

NBRV Latest News Stream

Event/Time News Detail
Loading, please wait...

NBRV Latest Social Stream

Loading social stream, please wait...

View Full NBRV Social Stream

Latest NBRV News From Around the Web

Below are the latest news stories about NABRIVA THERAPEUTICS PLC that investors may wish to consider to help them evaluate NBRV as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!

William White on InvestorPlace | April 5, 2023

7 Stocks to Sell as Banks Melt Down

Although the internet encourages you to buy the red ink, sometimes you should consider stocks to sell as just that.

Josh Enomoto on InvestorPlace | March 20, 2023

Nabriva Therapeutics Provides Corporate Update

-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations. As previously disclosed, the Company engaged Torreya Capital to

Yahoo | January 6, 2023

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

Yahoo | November 29, 2022

Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment

The Phase 1 study is testing the safety of oral and intravenous versions of lefamulin, the active ingredient in Xenleta, in adult patients with the condition.

Yahoo | November 28, 2022

Read More 'NBRV' Stories Here

NBRV Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -3.40%
3-year -96.06%
5-year -99.71%
2023 0.00%
2022 -87.38%
2021 -75.25%
2020 -81.67%
2019 -9.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!